CD26 Expression on T Cell Lines Increases SDF-1-Alpha-Mediated Invasion

Strategic Insights -

Researchers have made new discoveries in cancer, revealing the role of CD26 expression on T cell lines in enhancing SDF-1-alpha-mediated invasion. The study, conducted by researchers at the University of Florida, Division of Hematology-Oncology, found that CD26 expression leads to increased invasion in an in vitro system. The researchers investigated the involvement of CD26 in cell invasion and found that it enhances SDF-1-alpha-mediated invasion in a PI-3K and MEK1 pathway-dependent manner.

Key Takeaways:

  • CD26 is a multifunctional membrane-bound glycoprotein that regulates tumor growth in addition to its other activities.
  • The expression of CD26 in T cell lines leads to increased SDF-1-alpha-mediated invasion in an in vitro system.
  • The PI-3K and MEK1 pathways are involved in regulating CD26-associated enhancement of SDF-1-alpha-induced invasion.
  • CD45 may also be involved in mediating CD26 enhancement of invasion, but more studies are required to confirm this involvement.
  • The study used human T cell lines expressing different levels of CD26, including the parental CD26-positive T-lymphoblast cell line HSB-2 and clones infected with a retrovirus expressing siRNA vectors.
  • Flow cytometry and western immunoblotting were used to evaluate CD26 expression, CXCR4 expression, and phosphorylation of signalling kinases.
  • MMP-9 secretion and activity were measured by western immunoblotting and zymography of conditioned media, respectively.

Statistics:

  • The study used 3 different T cell lines, including HSB-2 and Jurkat.
  • CD26 expression was evaluated by flow cytometry and western immunoblotting.
  • CXCR4 expression, phosphorylation of signalling kinases, and MMP-9 secretion were evaluated by western immunoblotting.
  • MMP-9 activity was measured by zymography of conditioned media.
  • The study found that CD26 expression enhances SDF-1-alpha-mediated invasion by 20-30% in vitro.

Sources:

  • P.A. Havre et al., British Journal of Cancer, 2009;101(6):983-91.
  • Biotech Week editors, NewsRx.com, 2010.
  • University of Florida, Division of Hematology-Oncology, Gainesville, FL 32610 USA.